LBA
ATRA icon

Letko, Brosseau & Associates’s Atara Biotherapeutics ATRA Stock Holding History

Letko, Brosseau & Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-700
Closed -$12.1K – 105
2024
Q1 		$12.1K Hold
700
– – ﹤0.01% 102
2023
Q4 		$8.97K Hold
700
– – ﹤0.01% 96
2023
Q3 		$25.9K Hold
700
– – ﹤0.01% 98
2023
Q2 		$28.2K Hold
700
– – ﹤0.01% 94
2023
Q1 		$50.8K Hold
700
– – ﹤0.01% 89
2022
Q4 		$57.4K Buy
700
+72
+11% +$7.5K ﹤0.01% 97
2022
Q3 		$59K Hold
628
– – ﹤0.01% 99
2022
Q2 		$122K Hold
628
– – ﹤0.01% 95
2022
Q1 		$146K Hold
628
– – ﹤0.01% 98
2021
Q4 		$247K Buy
+628
New +$264K ﹤0.01% 101

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Letko, Brosseau & Associates's ATRA Position: Q2 2024 in Review

Letko, Brosseau & Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 700 shares — an estimated $12.1K sold.

Letko, Brosseau & Associates first reported a position in ATRA in Q4 2021 and held it in 10 quarters. The position peaked at $247K in Q4 2021. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Letko, Brosseau & Associates reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 700 Atara Biotherapeutics shares in Q2 2024, an estimated $12.1K.
  • Letko, Brosseau & Associates first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 10 quarters.
  • Letko, Brosseau & Associates's Atara Biotherapeutics position peaked at $247K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2024, filed 6 Aug 2024.